2026年3月17日 | 分析师 | 王班 | | --- | --- | | 邮箱 | wangban@stocke.com.cn | | 电话 | 15800935963 | | 证书编号 | S1230525070003 | | 分析师 | 安柯 | | --- | --- | | 邮箱 | anke@stocke.com.cn | | 电话 | 16625509126 | | 证书编号 | S1230525120003 | 摘要 证券研究报告 长风破浪正当时，直挂云帆济医海 医疗AI专题报告（一）：海外篇 1、AI医疗时代或来临，借鉴海外发展模式有必要 • 以Transformer为代表的大模型技术快速发展，对医疗行业有较大的影响。对医生、患者、医院、药企的工作有了很大的改 变，呈现出一定的颠覆潜力。但不同应用场景的成熟度存在显著差异。我们认为通过研究海外市场的数据共享机制、监管政 策取向、支付落地进展以及典型企业的商业模式，对于分析国内AI医疗企业具有一定的借鉴作用。 2、 海外产品、监管、支付流程已跑通，国内仍在完善中 2 添加标题 95% • 我们认为AI产品落地面临着数据交换是否顺畅、监管政策 ...

格隆汇3月16日丨医脉通(02192.HK)宣布，公司将于2026年3月26日（星期四）举行董事会会议，藉以考 虑及批准公司及其附属公司截至2025年12月31日止年度的全年业绩及其发布，并考虑派发末期股息（如 有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限責任公司） （股份代號：2192） 董事會會議日期 醫脈通科技有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公司 將於二零二六年三月二十六日（星期四）舉行董事會會議，藉以考慮及批准本 公司及其附屬公司截至二零二五年十二月三十一日止年度之全年業績及其發佈， 並考慮派發末期股息（如有）。 承董事會命 醫脈通科技有限公司 董事長及首席執行官 田立平 Medlive Technology Co., Ltd. 香港，二零二六年三月十六日 醫脈通科技有限公司 於本公告日期，董事會包括執行董事田立平女士、田立新先生、田立軍先生及周欣女士；非 執行董事槌屋英二先生及金色一賢先生；以及獨立非執行董事葉霖先生、馬軍醫師及王珊女士。 ...

Core Viewpoint - The company, 医脉通 (02192), announced the issuance of ordinary shares to a director and an employee as part of its pre-IPO share option plan adopted on March 29, 2021 [1] Group 1 - The company will issue 300,000 ordinary shares to a director exercising share options on March 4, 2026 [1] - The company will issue 25,000 ordinary shares to an employee exercising share options on March 4, 2026 [1]

Core Viewpoint - The company, 医脉通 (02192), announced the issuance of ordinary shares as part of its pre-IPO share option plan adopted on March 29, 2021 [1] Group 1 - The company will issue 300,000 ordinary shares to a director exercising share options on March 4, 2026 [1] - The company will also issue 25,000 ordinary shares to an employee exercising share options on the same date [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫脈通科技有限公司 呈交日期： 2026年3月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | | 02192 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已 ...

Core Viewpoint - FIL Limited has increased its stake in 医脉通 (Medlink) from 4.67% to 5.04% by purchasing 2.7155 million shares at an average price of HKD 9.6301 per share, totaling approximately HKD 26.1505 million [1][2]. Group 1 - FIL Limited acquired 2.7155 million shares of 医脉通 on February 24, 2026, at an average price of HKD 9.6301 per share [1][2]. - Following the acquisition, FIL Limited's total shareholding in 医脉通 increased to 37.1726 million shares [1][2]. - The ownership percentage of FIL Limited rose from 4.67% to 5.04% after the transaction [1][2].

Group 1 - FIL Limited increased its stake in Yimaitong (02192) by acquiring 2.7155 million shares at a price of HKD 9.6301 per share, totaling approximately HKD 26.1505 million [2][5] - After the acquisition, FIL Limited's total shareholding in Yimaitong reached approximately 37.1726 million shares, representing a new ownership percentage of 5.04% [2][5]

Core Viewpoint - FIL Limited has increased its stake in the company 医脉通 (02192) by acquiring 2.7155 million shares at a price of HKD 9.6301 per share, totaling approximately HKD 26.1505 million, resulting in a new holding of about 37.1726 million shares, representing 5.04% ownership [1] Group 1 - FIL Limited's acquisition of shares indicates a strategic investment in 医脉通, reflecting confidence in the company's future prospects [1] - The transaction involved related parties, specifically Pandanus Associates Inc. and Pandanus Partners L.P., suggesting potential collaborative interests or shared investment strategies [1] - The increase in shareholding percentage to 5.04% may influence market perception and investor sentiment towards 医脉通 [1]

Group 1 - FIL Limited increased its stake in Medical Information Technology (医脉通, 02192) by acquiring 2.7155 million shares at a price of HKD 9.6301 per share, totaling approximately HKD 26.1505 million [1] - After the acquisition, FIL Limited's total shareholding in Medical Information Technology reached approximately 37.1726 million shares, representing a stake of 5.04% [1] - The transaction involves related parties: Pandanus Associates Inc. and Pandanus Partners L.P. [1]